Baker McKenzie updates

Compliance with medical product shortage reporting requirements during COVID-19 pandemic
Baker McKenzie
  • Healthcare & Life Sciences
  • USA
  • 17 June 2020

The consequences of supply chain interruptions from a compliance perspective vary slightly, depending on the type of product and its indication. Human drug products and medical device products have different requirements for reporting supply chain disruptions and the impact of COVID-19 has cast a bright light on this inequity. Compliance with reporting requirements is therefore paramount during the ongoing pandemic.

Current search